Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow

Molecular Therapy

Volumn 15, Issue 9, 2007, Pages 1686-1693

  Breitbach, Caroline J ^a,b   Paterson, Jennifer M ^a,b   Lemay, Chantal G ^a,b   Falls, Theresa J ^a   McGuire, Allison ^b   Parato, Kelley A ^a   Stojdl, David F ^c   Daneshmand, Manijeh ^a   Speth, Kelly ^d   Kirn, David ^d   McCart, Andrea J ^e   Atkins, Harold ^a   Bell, John C ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d Jennerex Biotherapeutics   (United States)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; ONCOLYTIC VIRUS; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER; CELL ACTIVATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOLYTIC VIROTHERAPY; TRANSCRIPTION INITIATION; TUMOR BLOOD FLOW; TUMOR CELL DESTRUCTION; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; APOPTOSIS; BLOOD FLOW VELOCITY; CELL LINE, TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INFLAMMATION; MICE; MICE, INBRED BALB C; NEOPLASMS; NEUTROPHILS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VESICULAR STOMATITIS INDIANA VIRUS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 34548062828     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300215     Document Type: Article

References (46)

1. Parato, KA, Senger, D, Forsyth, PA and Bell, JC (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976.
2. Bell, JC, Lichty, B and Stojdl, D (2003). Getting oncolytic virus therapies off the ground. Cancer Cell 4: 7-11.
3. Ries, SJ and Brandts, CH (2004). Oncolytic viruses for the treatment of cancer: Current strategies and clinical trials. Drug Discov Today 9: 759-768.
4. Smith, ER and Chiocca, EA (2000). Oncolytic viruses as novel anticancer agents: Turning one scourge against another. Expert Opin Investig Drugs 9: 311-327.
5. Stojdl, DF, Lichty, B, tenOever, BR, Paterson, JM, Power, AT, Knowles, S et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
6. Bauerschmitz, GJ, Guse, K, Kanerva, A, Menzel, A, Herrmann, I, Desmond, RA et al. (2006). Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther 14: 164-174.
7. Ye, X, Jerebtsova, M and Ray, PE (2000). Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney. Hum Gene Ther 11: 621-627.
8. Chen, Y, Yu, DC, Charlton, D and Henderson, DR (2000). Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy. Hum Gene Ther 11: 1553-1567.
9. Ikeda, K, Wakimoto, H, Ichikawa, T, Jhung, S, Hochberg, FH, Louis, DN et al. (2000). Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 74: 4765-4775.
10. Jiang, H, Wang, Z, Serra, D, Frank, MM and Amalfitano, A (2004). Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol Ther 10: 1140-1142.
11. Lyons, M, Onion, D, Green, NK, Aslan, K, Rajaratnam, R, Bazam-Peregrino, M et al. (2006). Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther 14: 118-128.
12. Fisher, K (2006). Striking out at disseminated metastases: The systemic delivery of oncolytic viruses. Curr Opin Mol Ther 8: 301-313.
13. Shen, BH, Bauzon, M and Hermiston, TW (2006). The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p). Gene Ther 13: 986-990.
14. Parkins, CS, Stratford, MR, Dennis, MF, Stubbs, M and Chaplin, DJ (1997). The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion. Br J Cancer 75 319-323.
15. Liu, TC and Kirn, D (2007). Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions. Cancer Res 67: 429-432.
16. Alemany, R, Suzuki, K and Curiel, DT (2000). Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 81: 2605-2609.
17. Shayakhmetov, DM, Li, ZY, Ni, S and Lieber, A (2004). Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 78: 5368-5381.
18. Springer, ML, Ip, TK and Blau, HM (2000). Angiogenesis monitored by perfusion with a space-filling microbead suspension. Mol Ther 1 82-87.
19. Martinive, F, De Wever, J, Bouzin, C, Baudelet, C, Sonveaux, P, Gregoire, V et al. (2006). Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol Cancer Ther 5 1620-1627.
20. Goertz, DE, Yu, JL, Kerbel, RS, Burns, PN and Foster, FS (2002). High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res 62: 6371-6375.
21. McCart, JA, Ward, JM, Lee, J, Hu, Y, Alexander, HR, Libutti, SK et al. (2001). Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61: 8751-8757.
22. Bonizzi, G and Karin, M (2004). The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25 280-288.
23. Nathan, C (2006). Neutrophils and immunity: Challenges and opportunities. Nat Rev Immunol 6: 173-182.
24. Londhe, VA, Belperio, JA, Keane, MP, Burdick, MD, Xue, YY and Strieter, RM (2005). CXCR2 is critical for dsRNA-induced lung injury: Relevance to viral lung infection. J Inflamm (Lond) 2: 4.
25. Eltzschig, HK and Collard, CD (2004). Vascular ischaemia and reperfusion injury. Br Med Bull 70: 71-86.
26. Korthuis, RJ and Gute, DC (1997). Postischemic leukocyte/endothelial cell interaction and microvascular barrier dysfunction in skeletal muscle: Cellular mechanisms and effect of Daflon 500mg. Int J Microcirc Clin Exp 17 (suppl. 1): 11-17.
27. Harris, AG and Skalak, TC (1996). Effects of leukocyte capillary plugging in skeletal muscle ischemia-reperfusion injury. Am J Physiol 271: H2653-H2660.
28. Maus, U, von Grote, K, Kuziel, WA, Mack, M, Miller, EJ, Cihak, J et al. (2002). The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice. Am J Respir Crit Care Med 166: 268-273.
29. Tepper, RI, Coffman, RL and Leder, P (1992). An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257: 548-551.
30. Babior, BM (1984). Oxidants from phagocytes: Agents of defense and destruction. Blood 64: 959-966.
31. Henson, PM and Johnston, RB Jr. (1987). Tissue injury in inflammation. Oxidants, proteinases, and cationic proteins. J Clin Invest 79 669-674.
32. Carrell, RW (1986). α1-Antitrypsin: Molecular pathology, leukocytes, and tissue damage. J Clin Invest 78: 1427-1431.
33. Burns, AR, Smith, CW and Walker, DC (2003). Unique structural features that influence neutrophil emigration into the lung. Physiol Rev 83: 309-336.
34. Hashizume, H, Baluk, P. Morikawa, S, McLean, JW, Thurston, G, Roberge, S et al. (2000). Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156: 1363-1380.
35. Harlan, JM (1985). Leukocyte-endothelial interactions. Blood 65 513-525.
36. Schleiffenbaum, B, Fehr, J, Odermatt, B and Sperb, R (1998). Inhibition of leukocyte emigration induced during the systemic inflammatory reaction in vivo is not due to IL-8. J Immunol 161: 3631-3638.
37. Werfel, T, Oppermann, M, Schulze, M, Krieger, G, Weber, M and Gotze, O (1992). Binding of fluorescein-labeled anaphylatoxin C5a to human peripheral blood, spleen, and bone marrow leukocytes. Blood 79 152-160.
38. Blohm, U, Potthoff, D, van der Kogel, AJ and Pircher, H (2006). Solid tumors "melt" from the inside after successful CD8 T cell attack. Eur J Immunol 36: 468-477.
39. Reid, TR, Freeman, S, Post, L, McCormick, F and Sze, DY (2005). Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 12: 673-681.
40. Au, T, Thorne, S, Korn, WM, Sze, D, Kim, D and Reid, TR (2007). Minimal hepatic toxicity of Onyx-015: Spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer Gene Ther 14: 139-150.
41. Hu, JC, Coffin, RS, Davis, CJ, Graham, NJ, Groves, N, Guest, PJ et al. (2006). A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12: 6737-6747.
42. Fulci, G, Breymann, L, Gianni, D, Kurozomi, K, Rhee, SS, Yu, J et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 103: 12873-12878.
43. Markert, JM, Medlock, MD, Rabkin, SD, Gillespie, GY, Todo, T, Hunter, WD et al. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 7: 867-874.
44. Grote, D, Cattaneo, R and Fielding, AK (2003). Neutrophils contribute to the measles virus-induced antitumor effect: Enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res 63 6463-6468.
45. Power, AT, Wang, J, Falls, TJ, Paterson, JM, Parato, KA, Lichty, ED et al. (2007). Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 15: 123-130.
46. Desforges, M, Charron, J, Berard, S, Beausoleil, S, Stojdl, DF, Despars, G et al. (2001). Different host-cell shutoff strategies related to the matrix protein lead to persistence of vesicular stomatitis virus mutants on fibroblast cells. Virus Res 76: 87-102.